by Raynovich Rod | Mar 31, 2024 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-3 4/5/24 Steady gains with a lot of green. Small cap life science 2+% gains: CRMD, CRNX, CYTK,GERN, NTRA,RXRX,TWST. XBI holding at $90 level. Update-2 4/4/24 Stocks reversed after some early strength as small caps and momentum trades took a hit. Selling picked...
by Raynovich Rod | Mar 25, 2024 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-1 MRK up 5% to $131.81 on FDA approval of PAH (Pulmonary Arterial Hypertension) Drug. ABBV and LLY get small gains SUPN up 3.88%. Nice pick-up in momentum from our SMID trading list: ABOS, CPRX, CRMD, CYRX, PACB, ROIV,, VCEL, VCYT, etc, XBI up 2.38%. XLV...
by Raynovich Rod | Sep 26, 2023 | 2024 Rayno Biopharmaceuticals Portfolio, Macro
Update-4 10/7…We will update our biopharma playbook next week with a focus on large caps. Our current picks are: Abbvie (ABBV), Lilly (LLY), Regeneron (REGN), and Vertex (VRTX); Pfizer (PFE) is a contrarian trade for value and good news. Update-3 10/6…A...
by Raynovich Rod | May 22, 2023 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-2 5/27/23… Not a great week for healthcare stocks or anything other than IT and the QQQ up 3.59%. S&P 500 Healthcare down 2.93%, Materials down 3.14%, Staples down 3.21%. No debt ceiling deal, recession watch is on. So Karen Firestone, former manager...
by Raynovich Rod | May 15, 2023 | 2023-24 Life Science Portfolios
Update-2…May 19 1015a in early trading, stocks are opening on the green side. Biopharma stocks are trying to firm up after a spate of weakness from the FTC action on the AMGN/Horizon deal: ABBV, GILD, LLY, REGN, RHHBY MRK, VRTX. Update-1 May 17 …Broad...
by Raynovich Rod | May 8, 2023 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-1 5/9/23 Biotech holding up nicely. XBI up 1.48% to $86 handle. CRSP up 14% to $64 handle, NTLA up 2%. GILD in buying range under $80 with 3.76% dividend, FWD PE of 10.9 and strong position in HIV/Aids, viral hepatitis, coronaviruses and emerging portfolio in...
by Raynovich Rod | Sep 16, 2021 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Biotech Bounce in Mid-Small Caps- life science stocks find buyers. Bellwether tickers : ARKG up 3% to $83.93, XBI up 1.44% to $132.88. Update-1 …Triple witching selling pressure again as expected but a little green at the end of day. DJI down 0.48%, NASDAQ down...
by Raynovich Rod | Jun 11, 2021 | 2024 Rayno Biopharmaceuticals Portfolio
6/16 At close: Benign reaction from FED meeting. Maybe investors have accepted reality that low interest rates are not going to last forever and are less ebullient. Market needs a few days to digest Chairman Powell’s remarks. Rate hikes pushed out til 2023 but...
by Raynovich Rod | Jun 7, 2021 | 2024 Rayno Biopharmaceuticals Portfolio
Update-1 6/7/21 Biogen shares soar 38% to $395 handle as trading opens late in the day. Despite mixed opinions on the efficacy and cost of the drug many analysts and executives in the industry hail the FDA approval. It should boost the industry overall and provide a...
by Raynovich Rod | Feb 15, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 2/17-11a…Biopharma stocks up on a down day: ABBV, AZN, BMY, MRK, VRTX with IBB off 0.5%. Update-1 Continued Sell-off in Biopharma and now Coronavirus Stocks The market was flattish with slight gains for the DOW, Financials were strong with TSY yields...